Beam Therapeutics Holds Great Potential, But Patience Needed

Biotech firm's base-editing gene therapy and pipeline show promise, but investors must exercise caution

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Beam Therapeutics, a biotech company founded in 2017 and headquartered in Cambridge, MA, has generated significant investor interest due to its pioneering work in base-editing gene therapy. The company's lead candidates, risto-cel and BEAM-302, have shown promising results in clinical trials. However, the author cautions that patience is required, as Beam Therapeutics is still an early-stage company with a long road ahead before potential commercialization of its therapies.

Why it matters

Beam Therapeutics' base-editing technology represents a significant advancement in gene therapy, offering the potential to precisely correct genetic defects. If successful, the company's therapies could transform the treatment of various genetic diseases. However, the biotech industry is notoriously risky, and investors must weigh the company's potential against the challenges it faces in navigating the regulatory landscape and bringing its therapies to market.

The details

Beam Therapeutics was founded by renowned scientists David Liu, J. Keith Joung, and Feng Zhang, who have pioneered the development of base-editing technology. The company's lead candidates, risto-cel and BEAM-302, are currently in clinical trials for the treatment of genetic disorders. Risto-cel is being evaluated for the treatment of sickle cell disease, while BEAM-302 is being developed for the treatment of a rare genetic disorder called Duchenne muscular dystrophy. The author notes that Beam Therapeutics has a strong cash runway, which should allow it to continue advancing its pipeline, but cautions that the path to commercialization is long and fraught with uncertainty.

  • Beam Therapeutics was founded in 2017.
  • The company's lead candidates, risto-cel and BEAM-302, are currently in clinical trials.

The players

Beam Therapeutics Inc.

A biotech company founded in 2017 that is pioneering the development of base-editing gene therapy technologies.

David Liu

One of the co-founders of Beam Therapeutics and a renowned scientist in the field of gene editing.

J. Keith Joung

One of the co-founders of Beam Therapeutics and a leading expert in gene editing technologies.

Feng Zhang

One of the co-founders of Beam Therapeutics and a renowned scientist in the field of gene editing.

Got photos? Submit your photos here. ›

What they’re saying

“I believe the key to creating wealth is the slow accumulation of high quality assets, and the key to enjoying the process of investing is to mix this steady approach with some high risk/high reward opportunities, underappreciated turnaround plays, and transformative technologies.”

— Robert J. Lake, Investor (Seeking Alpha)

What’s next

Beam Therapeutics will need to continue advancing its pipeline of gene therapy candidates through clinical trials and regulatory approval processes. Investors will be closely watching the progress of risto-cel and BEAM-302, as well as any updates on the company's broader gene editing technology platform.

The takeaway

Beam Therapeutics represents a promising opportunity in the field of gene therapy, but investors must exercise patience and caution. The company's base-editing technology holds great potential, but the path to commercialization is long and fraught with uncertainty. Investors should carefully weigh the risks and rewards before investing in this early-stage biotech firm.